Vir Advances HBV, Flu Programs While Focused On COVID-19

Company Brought In Significant Cash Before And After Its IPO

Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.

Vir Biotechnology Inc. launched an initial public offering in October to keep progressing its immunological approaches to infectious diseases, including two clinical programs to treat hepatitis B virus (HBV) and prevent influenza A, and preclinical programs in HBV and HIV. Then the COVID-19 pandemic hit and the company’s stock price surged as it put forward multiple programs and entered into partnerships to prevent and treat the novel coronavirus.

At $30.55 per share as of 21 April, Vir is trading 52.8% higher than its $20 IPO price and 151.4%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

19 Jun 2025

• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Quick Listen: Scrip’s Five Must-Know Things

16 Jun 2025

• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

11 Jun 2025

• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

11 Jun 2025

• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.